Programmable nucleases, such as Cas9, are used for precise genome editing by homology-dependent repair (HDR) [1] [2] [3] . However, HDR efficiency is constrained by competition from other double-strand break (DSB) repair pathways, including non-homologous end-joining (NHEJ) 4 . We report the discovery of a genetically encoded inhibitor of 53BP1 that increases the efficiency of HDR-dependent genome editing in human and mouse cells. 53BP1 is a key regulator of DSB repair pathway choice in eukaryotic cells 4,5 and functions to favor NHEJ over HDR by suppressing end resection, which is the rate-limiting step in the initiation of HDR. We screened an existing combinatorial library of engineered ubiquitin variants 6 for inhibitors of 53BP1. Expression of one variant, named i53 (inhibitor of 53BP1), in human and mouse cells, blocked accumulation of 53BP1 at sites of DNA damage and improved gene targeting and chromosomal gene conversion with either double-stranded DNA or single-stranded oligonucleotide donors by up to 5.6-fold. Inhibition of 53BP1 is a robust method to increase efficiency of HDR-based precise genome editing.
l e t t e r s
Programmable nucleases, such as Cas9, are used for precise genome editing by homology-dependent repair (HDR) [1] [2] [3] . However, HDR efficiency is constrained by competition from other double-strand break (DSB) repair pathways, including non-homologous end-joining (NHEJ) 4 . We report the discovery of a genetically encoded inhibitor of 53BP1 that increases the efficiency of HDR-dependent genome editing in human and mouse cells. 53BP1 is a key regulator of DSB repair pathway choice in eukaryotic cells 4, 5 and functions to favor NHEJ over HDR by suppressing end resection, which is the rate-limiting step in the initiation of HDR. We screened an existing combinatorial library of engineered ubiquitin variants 6 for inhibitors of 53BP1. Expression of one variant, named i53 (inhibitor of 53BP1), in human and mouse cells, blocked accumulation of 53BP1 at sites of DNA damage and improved gene targeting and chromosomal gene conversion with either double-stranded DNA or single-stranded oligonucleotide donors by up to 5.6-fold. Inhibition of 53BP1 is a robust method to increase efficiency of HDR-based precise genome editing.
In human cells, the dominant pathway that mends two-ended DSBs, such as those created by programmable nucleases, is NHEJ. A key regulator of the choice between NHEJ and HDR is 53BP1 (encoded by TP53BP1 in human cells), a pro-NHEJ factor that limits homologous recombination (HR) in part by blocking DNA end resection, but also by inhibiting BRCA1 recruitment to DSB sites 7, 8 . We therefore reasoned that 53BP1 might make a suitable target for increasing rates of precise gene editing by HDR.
To identify inhibitors of 53BP1, we took advantage of a softrandomized library of ubiquitin variants (Ubvs) that was initially developed to identify inhibitors of ubiquitin-binding proteins 6 . 53BP1 accumulates at DSB sites by recognizing histone H2A ubiquitylated on Lys15 (H2AK15ub), and so we reasoned that it might be possible to identify Ubvs targeting the 53BP1 ubiquitin-dependent recruitment (UDR) domain involved in ubiquitylated histone recognition 9 . After five rounds of selection against a GST-53BP1 fragment containing the tandem Tudor domain and the UDR domain (residues 1484-1631; Fig. 1a ), ten unique phages were selected for retesting in enzymelinked immunosorbent assays (ELISAs) for binding to the 53BP1 Tudor-UDR region and to 14 other proteins, most of them known ubiquitin-binding proteins (Fig. 1b) . We identified five distinct Ubvs that bound selectively to 53BP1 (A10, A11, C08, G08 and H04; Fig. 1b,c) . Using GST fusion proteins of four of these five Ubvs and testing them in GST pull-down assays against maltose-binding protein (MBP) fused to either the Tudor domain (residues 1484-1603) or the Tudor-UDR fragment of 53BP1, we found that each Ubv bound to the MBP fusion containing only the 53BP1 Tudor domain, in addition to those also containing the UDR domain (Fig. 1d,e) . Because the UDR domain is apparently not required for binding to the Ubv, all further experiments were carried out with proteins containing solely the Tudor domain. We selected clone G08 for further analysis because the phage expressing it displayed the strongest binding by ELISA (Fig. 1b) and contained only seven mutations, the lowest number of amino acid substitutions among the selected Ubvs (Fig. 1c) .
Because the 53BP1 Tudor domain binds to dimethylated histone H4 Lys20 (H4K20me2) 10 , we next tested whether UbvG08-and H4K20me2-binding functions were mutually exclusive. We found that H4K20me2 peptides competed with UbvG08 for 53BP1 binding with a half-maximal competing concentration in the 100 µM to 300 µM range (Fig. 1f) . Since the dissociation constant (K d ) of the Inhibition of 53BP1 favors homology-dependent DNA repair and increases CrIsPr-Cas9 genome-editing efficiency l e t t e r s H4K20me2 peptide-53BP1 Tudor interaction is 20 µM 10 , the result of the H4K20me2 peptide competition implied that 53BP1 bound to UbvG08 with higher affinity than methyl-lysine peptides. Indeed, as assessed by isothermal titration calorimetry (ITC), UbvG08 bound to the 53BP1 Tudor domain with K d of 242 ± 52 nM (N = 3), two orders of magnitude tighter than the 53BP1-H4K20me2 interaction (Fig. 1g) . In contrast, a version of UbvG08 that reverted the L69P and V70L mutations to wild type (deficient mutants, indicated by "-DM"; see below for the rationale behind these mutations) did not display any detectable binding to the 53BP1 Tudor domain by ITC (Fig. 1g) .
To gain insight into the mechanism by which UbvG08 binds to 53BP1, we solved the crystal structure of UbvG08 bound to the 53BP1 Tudor domain (see Supplementary Table 1 for data collection and refinement statistics). Within the solved complex, the 53BP1 Tudor domain adopted a canonical mixed α-β fold identical to that reported in its apo state (1XNI; secondary structure root-mean-square l e t t e r s deviation (RMSD) of 1.0 Å) and in complex with a H4K20me2-derived peptide (2IG0; secondary structure RMSD of 1.1 Å; Supplementary  Fig. 1a ). UbvG08 displayed the expected ubiquitin-like fold consisting of a five-strand β-sheet (β1-5) buttressed against a single α-helix (α1) and a short 3 10 helix. However, the register of strand β5 was shifted four positions from its expected position, resulting in an increase in the length of the loop preceding strand β5 by four residues and a shortening of the C-terminal tail of β5 by four residues (Supplementary Fig. 1b,c) .
Complex formation was achieved by association of the β-sheet surface of UbvG08 centered on β1, β2 and β5, with the ligand-binding surface of the 53BP1 Tudor domain (Fig. 2a) . This surface on the Ubv is adjacent to, but distinct from, the I44-centred hydrophobic patch that mediates the majority of Ub-protein interactions 11 . The contact surfaces were extensive (buried surface area = 755.4 Å 2 ), and comprised a mixture of hydrophobic and hydrophilic residues (Fig. 2b , with notable interactions depicted in Fig. 2c) .
The high-affinity binding between UbvG08 and the Tudor domain of 53BP1 can be rationalized as follows. Whereas the sequence of UbvG08 differs from ubiquitin by seven residues, only four substitutions are well positioned on the contact surface to allow direct interaction of their side chains with 53BP1. Specifically, L70 (Val in Ub) forms favorable hydrophobic contacts with 53BP1 F1553 and L1547; L2 (Gln in Ub) forms favorable hydrophobic contacts with 53BP1 Y1500; and P69 (Leu in Ub) forms a favorable hydrophobic contact with 53BP1 Y1552 (Fig. 2c) . Additionally, K66 (Thr in Ub) is well positioned to form an electrostatic interaction with 53BP1 E1575 (Fig. 2c) .
Other substitutions in UbvG08 may contribute to enhanced binding by stabilizing a shift in the register of strand β5. The L62 mutation l e t t e r s (Gln in Ub) appears most important, as it resides at the initiating position of the normally tight loop preceding β5 in Ub ( Supplementary  Fig. 1d ). The L62 substitution causes a reorientation of the side chain from a solvent-exposed orientation (in Ub) to a buried position (in UbvG08) in the hydrophobic core, which would be disruptive to tightturn formation. Additionally, the substituted side chains of D64 (Glu in Ub) and K66 (Thr in Ub) occupy new positions in the enlarged solvent-exposed loop preceding β5, whereas in the absence of a register shift, they would occupy positions in strand β3 directly facing the Tudor domain where they might otherwise contribute suboptimal interactions with 53BP1 (Supplementary Fig. 1e ). The register difference in strand β5 adds an additional layer of complexity owing to the non-substituted R72 side-chain displaced by 17 Å from its expected position in Ub, allowing it to form a near ideal salt interaction with E1551 in the Tudor domain (Fig. 2c) .
To validate the structural model, we interrogated the respective binding surfaces with site-directed mutagenesis. We first assessed the impact of reverting each of the seven substitutions in UbvG08 to their Ub counterparts. The L2Q, L62Q, D64E, P69L and L70V reversions all reduced UbvG08 binding to 53BP1, with the P69L and L70V mutations having the strongest effect (Fig. 2d) . Indeed, simultaneous reversions of P69 and L70 to their Ub counterparts (Ubv08-DM) completely abolished UbvG08 binding to the 53BP1 Tudor domain, as measured by ITC (Fig. 1g) . In a converse set of experiments, simultaneous mutation of the equivalent residues in Ub into their UbvG08 counterparts was sufficient to convert Ub into a robust 53BP1-binding protein, as measured in pull-down assays (Fig. 2e) . We also assessed the importance of the non-substituted (i.e., the same as Ub) residues in UbvG08 (Fig. 2f) , as well as the residues on the 53BP1 Tudor domain predicted by our model to be engaged in key interactions ( Supplementary Fig. 2a,b) . These analyses strongly validated the structural model of the UbvG08-53BP1 interaction.
We next tested whether intracellular expression of UbvG08 inhibits 53BP1 in cells. We prepared Flag-tagged versions of UbvG08 and the l e t t e r s deficient mutant. The C-terminal di-glycine motif was removed to preclude its incorporation in the active ubiquitin pool, and we also incorporated an I44A mutation, which disables the majority of ubiquitin-dependent interactions 11 but does not affect the interaction of UbvG08 with 53BP1 (Fig. 2d) . This version of UbvG08 is referred to hereafter as 'i53' , for inhibitor of 53BP1, for reasons that will become apparent below.
When U-2-OS (U2OS) cells, transfected with vectors expressing i53 or its deficient mutant, were irradiated with a 10-Gy dose of X-rays, we observed that i53 but not the 53BP1-binding-defective deficient mutant strongly suppressed 53BP1 recruitment to DSB sites, as monitored by ionizing radiation focus formation (Fig. 3a,b) . The inhibition of focus formation was specific to 53BP1, as i53 did not affect γ-H2AX and BRCA1 focus formation ( Fig. 3a and Supplementary Fig. 3a) . Transfection of G1 cells with i53 also induced BRCA1 accumulation at DSB sites 7 to a similar extent as that caused by loss of 53BP1 (refs. 7,12) , providing a first clue that i53 not only inhibits 53BP1 recruitment to damaged chromatin but also acts as an inhibitor of 53BP1 function ( Fig. 3c and Supplementary Fig. 3b ). i53, but not its deficient mutant, efficiently retrieved 53BP1 in co-immunoprecipitation experiments (Fig. 3d) , suggesting that the inhibition of 53BP1 occurs through occlusion of the Tudor domain ligand-binding site.
Although UbvG08, the parent molecule of i53, shows a high degree of selectivity towards 53BP1 in ELISA assays (Fig. 1b) , we determined the repertoire of cellular proteins bound by i53. We generated 293T Flp-In/T-Rex cell lines that expressed Flag-tagged i53 or i53-DM under the control of a tetracycline-inducible promoter, as previously described 13 . Nine immunoprecipitation-mass spectrometry experiments were analyzed (three biological replicate immunoprecipitations each for control, i53-and i53-DM-expressing cell lines). The only protein found to interact with i53 in two or more experiments was 53BP1 (Supplementary Table 2 ). We conclude that i53 is a selective binder of 53BP1 in cells.
Loss of 53BP1 results in increased HDR levels 14 , making inhibitors of 53BP1 potential tools to manipulate DSB repair pathways during genome engineering reactions. However, the depletion of 53BP1 by 
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Relative editing (DM = 1) l e t t e r s short interfering RNA (siRNA), although near complete as determined by immunoblotting (Supplementary Fig. 4a ), is often insufficient to induce HDR in the well-characterized direct-repeat (DR)-GFP assay 15 ( Fig. 3e,f) . We therefore tested whether i53 affected gene conversion frequency and observed that i53 led to a 2.4-fold (±0.25) increase in gene conversion when compared to the empty vector control, whereas the i53-DM mutant had virtually no impact on gene conversion (1.25-fold ± 0.17; Fig. 3g and Supplementary Fig. 4b ). As a point of comparison, we compared i53 to SCR7, the reported inhibitor of the NHEJ factor DNA ligase IV 16 , which has been shown in some systems to increase homology-dependent repair 17, 18 . We also tested its related pyrazine analog, which has been proposed to be the active SCR7 analog (https://www.tocris.com/dispprod.php?ItemId=432017#. VvUhqt-rSRs). Under our experimental conditions, i53 was a more potent inducer of gene conversion, compared to both SCR7 and to SCR7 pyrazine, which had minimal impact in this assay ( Fig. 3h and Supplementary Fig. 4c ).
As an orthogonal approach, we next tested whether i53 expression increased the efficiency of gene targeting stimulated by CRISPRCas9, in assays that involve the introduction of the coding sequences of fluorescent proteins such as mClover, mAG or mCherry in frame with the coding regions of Lamin A (LMNA) 12, 19 or histone H2B (HIST1H2BK) 20 . Precise HDR results in the expression of fluorescent protein fusions that can be quantitated by flow cytometry. We first assessed gene targeting at the LMNA locus in U2OS cells, which are not responsive to SCR7 treatment 19 , suggesting that end-joining may not provide a strong barrier to HR at this locus. Similarly, inhibition of DNA-PK, a core NHEJ factor, with NU7441 resulted in only a 1.3-fold increase in gene targeting in this assay (Fig. 4a) . However, we observed that i53, but not the deficient mutant, increased gene targeting nearly twofold (from 4.8% ± 0.5% for the empty vector control to 8.6% ± 0.6% for the i53 condition). The gene-targeting efficiency in i53-expressing cells approached that of 53BP1-null cells (53BP1 −/− ) 12 , suggesting that the inhibition of 53BP1 was near complete. Introduction of i53 in 53BP1 −/− cells did not result in a further increase in gene targeting, demonstrating that the effect of i53 on HR is via inhibition of 53BP1. Combining DNA-PK inhibition and i53 only modestly increased gene targeting, in line with the function of 53BP1 in promoting NHEJ.
The experiments above were undertaken with i53, delivered using plasmid transfection. Since adeno-associated virus (AAV)-mediated gene delivery is a method of choice for the delivery of gene-editing components in vivo, we tested whether AAV-mediated delivery of i53 also stimulates HDR. AAV-delivered i53 stimulated gene conversion by 2.5-fold over deficient mutants in U2OS cells as shown by DR-GFP assays (Supplementary Fig. 4d,e) , indicating that sufficient i53 levels can be achieved by AAV delivery. We next used AAV-mediated i53 delivery to assess its ability to stimulate homology-driven insertion of the coding sequence for the fluorescent protein mAG at the 3′ end of the HIST1H2BK open reading frame. In those experiments, 293T or K562 cells were nucleofected with Cas9-sgRNA ribonucleoprotein (RNP) complexes and double-stranded DNA (dsDNA) plasmid donors. i53 stimulated gene targeting at the HIST1H2BK locus in both 293T and K562 cells (1.3-fold and 1.8-fold, respectively) ( Supplementary  Fig. 5a,b) . The simultaneous nucleofection of donors inserting either mAG or mCherry at the HIST1H2BK locus next allowed us to estimate bi-allelic modification of this locus by monitoring cells that simultaneously express both fluorescent proteins 20 . We observed that i53 stimulated bi-allelic gene targeting 1.9-fold at the HIST1H2BK locus in K562 cells (Fig 4b and Supplementary Fig. 5c ).
In parallel, we also assessed whether AAV-delivered i53 could stimulate HDR in mouse cells. We employed a gene-targeting assay conceptually similar to those described above where the incorporation of a t2A-ZsGreen cassette at the Hsp90ab1 locus is monitored by flow cytometry. We found that i53 stimulated gene targeting in mouse embryo fibroblasts 2.3-fold over deficient mutants ( Fig. 4c and  Supplementary Fig. 6 ), indicating that AAV-mediated i53 stimulates HDR in both human and mouse cells.
In addition to AAV-mediated delivery, delivery of mRNA is another means for introducing gene-editing components in primary cells 21, 22 . We therefore tested whether electroporation of an i53-coding mRNA stimulated zinc finger nuclease (ZFN)-mediated gene targeting at the CCR5 locus in K562 using a dsDNA donor used previously 22, 23 . We found that mRNA delivery of i53 robustly increased gene targeting stimulated by a ZFN up to 5.6-fold over deficient mutants (Fig 4d) and resulted in a corresponding decrease of indels at the site of cleavage, as detected by the CEL1 nuclease (Supplementary Fig. 7a ). These results indicate that i53-mediated stimulation of HDR is independent of nuclease or delivery methods, and they suggest that i53 acts by skewing DSB repair pathway choice towards HDR.
Canonical, RAD51-dependent HDR is the dominant pathway for gene conversion with large dsDNA donors 24 . In contrast, HDR using single-stranded oligodeoxynucleotide (ssODN) donors involves a poorly understood RAD51-independent annealing-type mechanism 25 . We therefore examined the impact of i53 on the ssODNmediated conversion of GFP to BFP in 293T and MCF10a cells following a Cas9-induced DSB, as previously described 26 (Fig 4e  and Supplementary Fig. 7b,c) . We observed, with both optimal and suboptimal ssODN donors, that i53 stimulated HDR in this assay by ~30-40%, depending on the donor and cell line used. We next modified two endogenous loci, CXCR4 and CCR5, to introduce new restriction endonuclease sites by ssODN-mediated HDR in both 293T and K562 cells. We observed that i53 stimulated HDR with ssODN donors up to 3.3 (± 0.8)-fold in 293T cells and up to 1.8 (± 0.4)-fold in K562 cells (Fig 4f,g and Supplementary Fig. 7d,e) , with a concomitant decrease in indel formation at the same loci (Supplementary Fig. 7f ). These data indicate that i53 stimulates HDR with ssODN donors at multiple loci and cell types. Notably, these data also suggest that DNA end resection plays an important role in ssODN-mediated HDR. In support of this idea, depletion of CtIP, a key end-resection factor 4 , reduced HDR by ssODN in 293T cells by nearly 50% in the GFP-to-BFP conversion assay (Fig 4h and Supplementary Fig. 8a,b) .
DNA end resection inhibits NHEJ but can activate alternative end-joining pathways in addition to activating HR 27 . Resection can reveal regions of microhomology that may be rejoined in a process termed microhomology-mediated end joining (MMEJ) 27 . The impact of 53BP1 on this repair process is unclear owing to conflicting results 28, 29 . To assess whether i53 increases MMEJ, we employed the EJ2-GFP reporter assay 30, 31 . We found that i53 expression increased MMEJ (1.4 ± 0.2-fold over the empty vector; Supplementary  Fig. 8c,d ) but because the expression of the deficient mutant also increased MMEJ to a similar extent (1.3 ± 0.1-fold), it is unlikely that the increase was due to 53BP1 inhibition.
In summary, we report the development of a genetically encoded inhibitor of 53BP1 that robustly stimulates canonical and ssODNmediated homology-directed repair of DSBs. In addition to gene targeting applications, i53 could be useful in additional gene editing reactions (e.g., interparalog gene conversion reactions). Notably, i53 expression does not affect spontaneous or DNA-damage-stimulated sister l e t t e r s chromatid exchanges, a potential threat to genome stability that occurs as a consequence of crossover reactions (Supplementary Fig. 8e-h) .
The 53BP1 Tudor domain is highly conserved across a wide range of vertebrate species, including agriculturally important animals such as pigs and cows; and we have shown that i53 can also stimulate HDR in mouse cells. Thus, we expect that i53 could be used to stimulate HR in other species as well.
The observation that i53 stimulates HDR by ssODNs led us to ask whether CtIP, a key resection factor, also promotes this type of gene editing reaction. This is in line with the annealing-driven strand synthesis (ADSS) and single-stranded template repair (SSTR) models of HDR by ssODNs 25, 32 , which both suggest that end resection creates annealing targets for oligonucleotides. Notably, CtIP depletion led to only a ~50% reduction in HDR by ssODN, raising the possibility that multiple HDR pathways operate at DSBs or that Cas9-mediated cleavage might engage CtIP-independent resection. Deciphering how these pathways operate should suggest new opportunities for intervention and synergy with 53BP1 inhibition.
The versatility of the ubiquitin scaffold onto which i53 is built, along with the determination of the molecular basis of the i53-53BP1 interaction, should enable us to improve 53BP1 inhibition, either through protein engineering or through affinity maturation of the UbvG08 via additional rounds of mutagenesis and phage display selections. We therefore propose that 53BP1 inhibition be considered a propitious alternative for boosting HDR rates, which can also be used in combination with other methods, such as the recently described marker-free co-selection strategy based on the modification of the ATP1A1 gene 20 .
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Cell culture and treatments. U-2-OS (U2OS) and 293T cells were obtained from American Type Culture Collection (ATCC). 293T and HEK293 FlpIn/T-REx cells (Invitrogen) were propagated in DMEM medium supplemented with 10% FBS (FBS, Gibco) and 2 mM l-alanyl-l-glutamine, and were maintained in a 37 °C and 5% CO 2 atmosphere. U2OS cells were grown in McCoy's medium supplemented with 10% FBS. U2OS DR-GFP and EJ2-GFP cells were a gift of Jeremy Stark. 53BP1∆ U2OS and U2OS cell lines stably expressing CtIP-T847E were previously described 12 . Mouse embryonic fibroblasts (MEFs) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS (FBS) (Gibco), 2 mM l-glutamine (Sigma), 100 U/ml penicillin (Sigma), 0.1 µg/ml streptomycin (Sigma), 0.1 mM non-essential amino acids (Invitrogen), and 1 mM sodium pyruvate (Sigma).
All cell lines tested negative for mycoplasma contamination and the identity of cell lines were confirmed by short tandem repeat (STR)analysis.
Plasmids. The phagemid (DDp2235) from the UbvG08 phage was obtained from the ubiquitin variant library, as described 6 ; see below for details. The UbvG08 open reading frame (ORF) lacking the C-terminal di-Gly residues was cloned into a pDONR vector using a product from PCR amplification of the phagemid template and Gateway recombination, yielding plasmid DDp2251 (UbvG08 ∆GG). The pETM-30-2-GST-UbvG08 (DDp2186) and pETM30-2-GST-ubiquitin (DDp2192) were cloned following PCR amplification from the UbvG08∆GG or Ub∆GG ORFs, respectively. The constructs encoding His6-GST-TEV and MBP fusions of 53BP1 Tudor-UDR (residues 1484-1631) and Tudor (residues 1484-1603) domains were described previously 9 . The I44A mutation was introduced into DDp2186, which was then used as a template for amplification of the modified Ubv by PCR. The PCR product was cloned into the BamHI and NotI sites of a pcDNA3-Flag plasmid to yield pcDNA3-Flag-i53 (DDp2534). The BamHI-NotI fragment of DDp2534 was subsequently cloned into a pcDNA5-Flag-FRT/TO Flag vector to yield plasmid DDp2535. All other plasmids were generated by site-directed mutagenesis carried out by Quikchange (Agilent). The plasmids used for the LMNA assay were gifts of G. Dellaire 19 .
Single guide (sg)RNAs targeting TP53 (CAGAATGCAAGAAGCCCAGA), BRCA1 (AAGGGTAGCTGTTAGAAGGC) and 53BP1 (TCCAATCCTGA ACAAACAGC) were cloned into lentiGuide-Puro (Addgene: #52963) as described 34 . The i53 and DM lentiviral expression vectors were prepared by PCR amplification that also introduced sequences coding for an N-terminal HA-tag and flanking PacI and NotI restriction sites. The PCR products were cloned in the PacI and NotI sites of pMX-IRES-GFP (a gift from A. Nussenzweig, National Institutes of Health). The Lenti-Cas9-2A-Blast construct was a gift from J. Moffat (University of Toronto). All constructs were sequence-verified.
To prepare AAV-i53 and i53-DM vectors, the region comprising Flag-i53 (or i53-DM) was PCR-amplified from pcDNA3-i53 and pcDNA3-i53-DM with the addition of a 5′ ClaI site and 3′ HindIII site. The GFP insert was excised from pAAV-GFP (Cell Biolabs) and replaced with the ClaI-and HindIII-flanked Flag-UbV PCR products to produce pAAV-Flag-i53-DM and pAAV-Flag-i53, which were verified by diagnostic digests and sequencing.
To facilitate monitoring of mono-versus bi-allelic editing, the mAG coding sequence in the HISTH2BK-mAG donor plasmid (gift of Y. Doyon) was exchanged for mCherry. The mCherry gene was amplified by PCR from a pCDNA5-FRT/TO-mCherry plasmid, flanked by a 5′ KpnI site and a 3′ BsrGI site. The reverse primer simultaneously served to silently mutate a naturally occurring BsrGI site at the 3′ end of the mCherry sequence. The PCR product and HISTH2BK-mAG1 plasmid were digested with KpnI and BsrGI, and gelpurified. The PCR fragment was then ligated into the HISTH2BK donor vector, and clones were screened by diagnostic digest, and confirmed by sequencing.
The vectors pcDNA3-Flag-i53 (#74939), pcDNA3-Flag-i53-DM (#74940), pAAV-Flag-i53 (#92170) and pAAV-Flag-i53-DM (#92171) have been deposited at Addgene.
Selection and purification of the 53BP1-binding ubiquitin variants.
The phage-displayed Ubv library used in this study was re-amplified from Library 2 as previously described 6 . Protein immobilization and subsequent phage selections were performed according to established protocols 35 . Briefly, purified 53BP1 protein fragments were coated on 96-well MaxiSorp plates (Thermo Scientific 12565135) by adding 100 µL of 1 µM proteins and incubating overnight at 4 °C. Afterwards, five rounds of selection using the phagedisplayed Ubv library were performed against immobilized proteins. A total of 96 phage clones obtained from the fourth and the fifth round of binding selections (48 from each round) were subjected to clonal ELISA to identify individual phages that bound to 53BP1. The sequences of phage-displayed Ubvs were derived by sequencing of the phagemid DNA 35 . For phage ELISA, proteins in the study (53BP1 and/or control proteins) were immobilized on 384-well MaxiSorp plates (Thermo Scientific 12665347) by adding 30 µL of 1 µM proteins for overnight incubation at 4 °C before adding amplified phages (1:3 dilution in PBS + 1% BSA + 0.05% Tween) and incubated overnight. Binding of phage was detected using anti-M13-HRP antibody (GE Healthcare 27942101).
Pull-downs. MBP and GST pull-downs were done essentially as described 9 with the modifications described below. We used the following buffer for the binding reactions: 50 mM Tris-Cl pH 7.5, 50 mM NaCl, 0.01% NP40 and 1% BSA. We also used 2.5 µg of the MBP-and GST-fusion proteins as baits. For peptide competition pull-downs 2.5 µg MBP-53BP1-Tudor was coupled to amylose resin (New England Biolabs) and 0.75 µg GST-UbvG08 was added first to the 53BP1 resin prior to incubation with a biotin-labeled peptide derived from histone H4K20me2 (BiotinMini-PEG-YGKGGAKRHRKme2VLRD; BioBasic Canada Inc.) for 2 h at 4 °C. Peptide pull-downs were washed in binding buffer, eluted with SDS-PAGE sample buffer, and analyzed by immunoblotting. For all pull-downs, 1-2% of the total amount of the input proteins was separated by SDS-PAGE and probed for immunoblotting.
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Protein expression, crystallization and structure determination. The 53BP1 Tudor domain (residues 1784-1603) and UbvG08 were individually expressed and purified from bacteria as GST-tagged fusion proteins. In brief, GST-tagged fusion proteins were purified from bacterial lysates on to glutathione-Sepharose (GE Healthcare), washed, and then eluted by TEV protease digestion to GST moieties, followed by purification by size-exclusion chromatography (SEC). The 53BP1 Tudor-UbvG08 complex was formed by mixing purified proteins at equimolar concentration, incubating overnight at 4 °C, and purifying the complex by SEC in 10 mM Tris-Cl pH 7.5, 150 mM NaCl and 1 mM DTT column buffer. Crystals of the complex were grown at 20 °C using the hanging drop vapor diffusion method by mixing equal volumes (1 µL) of complex at 28.5 mg/ml with crystallization buffer consisting of 0.1 M MES (2-(N-morpholino)ethanesulfonic acid) pH 6.0, 0.2 M trimethylamine N-oxide and 25% (w/v) PEG MME (polyethylene glycol monomethyl ether) 2000. Crystals were cryo-protected by a quick soak in crystallization buffer supplemented with 20% glycerol, before flash freezing. A single crystal data set was collected at −180 °C on a Rigaku MicroMax-007 HF rotating anode generator, coupled to a R-axis 4++ detector (Rigaku) and VariMax multilayer optics. Data processing was performed using the XDS software suite. The structure of a single 53BP1 Tudor-UbvG08 complex in the asymmetric unit was solved by molecular replacement using the apo Tudor domain (PDB 2IG0) and ubiquitin (PDB 3NHE chain B) as search models in Phaser (Phenix suite). Structure refinement was performed using Refine (Phenix suite). See Supplementary Table 1 for data collection and refinement statistics.
Immunoprecipitation. 293T cells were transfected with 10 µg of pcDNA3-Flag-i53-derived plasmids using polyethylenimine (PEI). 48 h after transfection, cells were lysed in 1 mL high-salt lysis buffer (50 mM Tris-HCl pH 7.6, 300 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, and 1× protease inhibitors (Complete, EDTA-free, Roche)) and cell lysates were clarified by centrifugation at 4 °C. 100 µL was removed as the input sample. The remaining lysate was incubated with ~15 µL anti-Flag (M2) affinity gel (Sigma) for 2 h at 4 °C. The immunoprecipitates were then washed twice with high-salt lysis buffer, once with 50 mM Tris-HCl pH 8.0, 0.1 mM EDTA and eluted in 25 µL 2× Laemmli sample buffer for analysis by immunoblotting. Xcessbio) and SCR7pyrazine (#5342l; Tocris) at 1 µM. Olaparib was purchased from Selleck Chemicals.
AAV production. The viral supernatant of AAV293 cells (Agilent Technologies) was collected and used for infections 48 h after co-transfection with 3.5 µg each of expression plasmid, pDJ and pHelper (Cell BioLabs). For MEFs, the viral supernatant was first concentrated in Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-100 membrane.
Preparation of RNPs. Purified SpCas9 was diluted to a concentration of 3.2 µg/µl in Cas9 buffer (20 mM HEPES (pH 7.5), 150 mM KCl, 1 mM MgCl 2 , 10% glycerol and 1 mM TCEP (Tris(2-carboxyethyl)phosphine)), and sgRNA was diluted to a concentration of 0.8 µg/µl in Cas9 buffer. 5 µl of diluted Cas9 was slowly mixed into 5 µl of diluted sgRNA, then incubated for 10-20 min at room temperature.
Immunofluorescence microscopy. Cells were grown on glass coverslips, fixed with 2% (w/v) paraformaldehyde in PBS for 20 min at room temperature, permeabilized with 0.3% (v/v) Triton X-100 for 20 min at room temperature and blocked with 5% BSA in PBS for 30 min at room temperature. Cells were then incubated with the primary antibody diluted in PBS-BSA for 2 h at room temperature. Cells were next washed with PBS and then incubated with secondary antibodies diluted in PBS-BSA supplemented with 0.8 µg ml −1 of DAPI (Sigma) to stain DNA for 1 h at room temperature. The coverslips were mounted onto glass slides with Prolong Gold mounting agent (Invitrogen). Confocal images were taken using a Zeiss LSM780 laser-scanning microscope.
10 5 cells were resuspended in 20 µl SF buffer (Lonza) and nucleofected with 10 µl sgBFP RNP and 100 pmol of ssODN donor, using program DS-150 on a Nucleofector 96-well Shuttle system (Lonza). Cells were then transferred to a 12-well plate containing pre-warmed medium, and grown for 4 d. BFP and GFP fluorescence were measured by flow cytometry on a BD Fortessa, and the results were analyzed using FlowJo v10 software.
ssODN-based RFLP HDR assay. The day after AAV transduction 2 × 10 5 cells were resuspended in 20 µl SF buffer (Lonza) and nucleofected along with 10 µl sgCCR5 or sgCXCR4 RNPs and 100 pmol of ssODN donor, using program FF-120 (for K562 cells) or DS-150 (for 293T cells), respectively, on a Nucleofector 96-well Shuttle system (Lonza). Cells were collected 3 d after nucleofection and their genomic DNA isolated (Qiagen DNeasy kit). The CCR5 and CXCR4 loci were amplified by PCR from 400 ng of genomic DNA using Pfx Platinum Polymerase (Invitrogen). 200 ng of purified PCR product was digested overnight with PciI (NEB), then resolved on a 2% agarose gel and analyzed with ImageQuant software.
Mass spectrometry. Following immunoprecipitation of Flag-tagged UbvG08 and UbvG08DM from HEK293 Flp-In/T-REx cells, peptides were identified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Proteins were digested in solution with trypsin (Sigma, T7575-1KT) and dried to completeness. For LC-MS/MS analysis, peptides were reconstituted in 5% formic acid and loaded onto a 12-to 15-cm fused silica column with pulled tip packed in-house with 3.5 µm Zorbax C18 (Agilent Technologies, CA, USA). UbvG08 and UbvG08-DM were analyzed using an LTQ (Thermo Scientific) coupled to an Agilent 1100 Series HPLC (Agilent Technologies). Peptides were eluted from the column using a 90-min-period cycle with a linear gradient from 0% to 40% ACN in 0.1% formic acid. Tandem MS spectra were acquired in a data-dependent mode for the top five most abundant ions using collision-induced dissociation. Acquired spectra were searched against the human Refseq_V53 database using Mascot (Matrix Science).
Isothermal titration calorimetry. Isothermal titration calorimetry was performed using a VP-ITC calorimeter (MicroCal). Untagged 53BP1 Tudor and UbvG08 (or the DM mutant) were dialyzed into PBS and degassed. 100 µM UbvG08 in the syringe was titrated into 10 µM 53BP1 Tudor protein in the sample cell using 30 consecutive 10 µl injections at 25 °C. Resultant binding isotherms were processed with Origin 5.0 software (MicroCal). Curve fits were carried out using the one-set-of-sites model.
ZFN editing reagents.
A ZFN pair targeting CCR5 has been previously described 22, 36 . The ZFN coding sequences were cloned into pVAX (Thermo Fisher Scientific, Waltham, MA), which was linearized by restriction enzyme digestion to generate templates for mRNA synthesis, using the mMESSAGE mMACHINE T7 ULTRA Kit (Thermo Fisher Scientific), according to the manufacturer's instructions. A CCR5 homologous sequence 22 containing an internal XhoI restriction site, was used in its plasmid form as a homology donor.
Analysis of gene disruption and editing by ZFNs. K562 cells were obtained from the American Type Culture Collection, and transfected by nucleofection as previously described 23 , using 16-well Nucleocuvette Strips in the 4D-Nucleofector System, and the SF Cell Line 4D-Nucleofector X Kit S (Lonza, Cologne, Germany). Briefly, 2 × 10 5 cells were resuspended in 20 µL of SF solution, together with mRNA and/or plasmids, and nucleofected using the recommended program for K562 cells. Two sequential nucleofections were performed, 24 h apart, to allow i53 or DM expression before delivery of ZFN mRNA and donor plasmids. Cells were recounted and normalized before the second nucleofection. A total of 2.1, 4.2 or 6.3 pmol of i53/DM mRNAs, 1.8 pmol of each ZFN mRNA and/or 0.3 pmol of donor plasmids were used. K562 cell pellets were harvested 5 d after the last nucleofection and CCR5 gene disruption rates determined using GeneArt Genomic Cleavage Detection Kit (Thermo Fisher Scientific) following the manufacturer's instructions. Briefly, genomic DNA was extracted from cell pellets and subject to PCR amplification using human CCR5-specific primers 22 . The PCR product was then denatured and reannealed in conditions allowing small DNA mismatch reannealing, and a proprietary detection enzyme was added to cleave unmatched regions. Digested PCR products were subject to electrophoresis on a 10% polyacrylamide gel, and gene disruption rates determined based on densitometry analysis of cleaved and uncleaved products. Gene editing rates were determined using an RFLP assay, as described 22, 23 . Briefly, a pair of CCR5 primers located outside the region of homology contained within the CCR5 donor molecule was used for PCR amplification, followed by XhoI digestion, resolution on a 1% agarose gel and analysis of products by densitometry. Figures 1-4 and Supplementary Figures 1-8 are provided with the paper in Supplementary Data. The structure data were deposited at the RCSB protein data bank (accession # PDB 5J26). Additional information can be found in the Life Sciences Reporting Summary. 33 
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Data exclusions
Describe any data exclusions. There was only one data exclusion (experiment in Figure 4b ). It was determined in the experiment that the i53 expression was unusually low due to low viral titer so one set of datapoint was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
The core assertion of this manuscript is that i53 is a robust and versatile tool for HDR-based genome editing. In the revised manuscript, we now have 3 independent groups confirming this finding.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
There was no randomization in this study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
There was no data blinding.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
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Data presentation
For all flow cytometry data, confirm that:
1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots. For the DR-GFP assay, the boundary between GFP-negative and GFPpositive was drawn from the plots of control samples where cells hadn't been transfected with IsceI.
For examples of how boundaries between "positive" and "negative" cells were drawn in the H2B-tagging assay, please see Supplemental Figure 5c .
For examples of how boundaries between "positive" and "negative" cells were drawn in the BFP-to-GFP assay, please see Supplemental Figures 7c and 8a.
For the ZsGreen Hsp90a1 targeting assay, live cells were gated from the FSC/SSC plots to exclude events of very low or very high FSC and/or SSC. The fraction constituted >80% of total events. The boundary between ZsGreen-negative and ZsGreen-positive was drawn according to control samples that were not transfected. FITC voltage was established in order to confine the negative population below 10*3 and positive population no further than 10*5
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
